redspeed: My son and I were at the Santa Monica Conference back in April I think when Gerald announced they had "identified a partner for LymPro." He referred to that partnership agreement a few other times in the months that followed and said we'd have a LymPro Partnership agreement by "the end of summer." Instead, we got a master service agreement with ICON. Gerald knew all the shareholders were thinking of the word "partner" in the "classic" sense where we'd get some up front cash, but he never bothered to correct that assumption. He even addressed that in his ICON PR saying it wasn't a "classic partnership." I think this disappointment following the July Conferences disappointment, followed by the inadequate LymPro revenue guidance have been what's held the pps down here below .08 cents.
I think most of us assumed several months ago that we'd already have up listed and be on our way by December 17th. So several milestones have been delayed significantly.
Has the company made progress? Yes, of course. And while some like jacmar could care less if the stock price moves down to .05 cents and stays there for a year, I'm not here for that. So the missed and delayed milestones in 2014 have disappointed investors like myself. Those of us who have hung on are betting that Gerald will finally actually deliver on the shareholder value he's been talking about. We'll know more in the coming days and weeks.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links